113 related articles for article (PubMed ID: 20150913)
1. c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3.
Li X; Ma Q; Wang J; Liu X; Yang Y; Zhao H; Wang Y; Jin Y; Zeng J; Li J; Song L; Li X; Li P; Qian X; Cao C
Cell Death Differ; 2010 Aug; 17(8):1277-87. PubMed ID: 20150913
[TBL] [Abstract][Full Text] [Related]
2. Interaction between c-Abl and Arg tyrosine kinases and proteasome subunit PSMA7 regulates proteasome degradation.
Liu X; Huang W; Li C; Li P; Yuan J; Li X; Qiu XB; Ma Q; Cao C
Mol Cell; 2006 May; 22(3):317-27. PubMed ID: 16678104
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
4. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
5. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
6. Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor.
Yu HH; Zisch AH; Dodelet VC; Pasquale EB
Oncogene; 2001 Jul; 20(30):3995-4006. PubMed ID: 11494128
[TBL] [Abstract][Full Text] [Related]
7. Non-receptor tyrosine kinases c-Abl and Arg regulate the activity of C/EBPbeta.
Li X; Liu X; Wang G; Zhu X; Qu X; Li X; Yang Y; Peng L; Li C; Li P; Huang W; Ma Q; Cao C
J Mol Biol; 2009 Aug; 391(4):729-43. PubMed ID: 19563810
[TBL] [Abstract][Full Text] [Related]
8. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
10. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Liu J; Wu Y; Arlinghaus RB
Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
[TBL] [Abstract][Full Text] [Related]
11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
12. Catalase is regulated by ubiquitination and proteosomal degradation. Role of the c-Abl and Arg tyrosine kinases.
Cao C; Leng Y; Liu X; Yi Y; Li P; Kufe D
Biochemistry; 2003 Sep; 42(35):10348-53. PubMed ID: 12950161
[TBL] [Abstract][Full Text] [Related]
13. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
[TBL] [Abstract][Full Text] [Related]
14. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
17. Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded.
Buffa P; Manzella L; Consoli ML; Messina A; Vigneri P
Proteins; 2007 Apr; 67(1):1-11. PubMed ID: 17211892
[TBL] [Abstract][Full Text] [Related]
18. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility.
Poppe M; Feller SM; Römer G; Wessler S
Oncogene; 2007 May; 26(24):3462-72. PubMed ID: 17160020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
